BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...

The follow-up brought little surprise, with investigators pleased the risk of death/disabling stroke remained on par with ...

Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut ...

Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...

Researchers found that at five years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke.

The “passive” notification led to more patients with severe AS undergoing valve replacement, but more can be done still.

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

The Evolut Low Risk Trial was a randomized ... and durable alternative to surgery for patients with severe aortic stenosis, regardless of their surgical risk," said Michael J.

system in low-risk aortic stenosis individuals. According to the company, the system exhibited “durable” clinical results and “strong” valve performance during the study. The multi-centre ...